Malmø-selskab henter millioninvestering før børsnotering

Ascelia Pharma med danske Magnus Corfitzen i spidsen har hentet 60 mio. svenske kroner hos blandt andre Sunstone. Investeringen skal bringe selskabet den sidste vej til et fase 3-studie, der skal finanseres via en børsnotering.
Photo: Ritzau Scanpix/AP/Evan Vucci
Photo: Ritzau Scanpix/AP/Evan Vucci
AF MIKKEL AABENHUS HEMMINGSEN

Malmø-baserede Ascelia Pharma har sikret sig finansieringer til at afslutte det forberedende arbejde til et kommende fase 3-studie med hovedaktivet Mangoral.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
  • Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
    Must contain at least 2 characters
    Must contain at least 2 characters

    Get full access for you and your coworkers

    Start a free company trial today

    Share article

    Sign up for our newsletter

    Stay ahead of development by receiving our newsletter on the latest sector knowledge.

    Newsletter terms

    Further reading